Biliary Tract Cancer Market Size in the 7MM was ~USD 1000 million, is expected to grow by 2034, estimated DelveInsight
DelveInsight’s “Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Biliary Tract Cancer market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
The Biliary Tract Cancer Market is an evolving segment of the global healthcare landscape, driven by the increasing Biliary Tract Cancer prevalence of the disorder and the continuous development of innovative treatment options. The Biliary Tract Cancer market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.
Discover Key Insights into the Biliary Tract Cancer Market with DelveInsight’s In-Depth Report @ Biliary Tract Cancer Market Size
Key Takeaways from the Biliary Tract Cancer Market Report
- In November 2024:- AbbVie- ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called cohorts. Each cohort receives ABBV-400 alone (monotherapy) followed by a safety follow-up period. Approximately 260 adult participants with hepatocellular carcinoma (HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), esophageal squamous cell carcinoma (ESCC), triple negative breast cancer (TNBC), hormone receptor+/human epidermal growth factor receptor 2 negative (HER2-) breast cancer (hormone receptor-positive [HR+]/HER2-breast cancer [BC]), head and neck squamous-cell-carcinoma (HNSCC), Platinum Resistant High Grade Epithelial Ovarian Cancer (PROC)/primary peritoneal/fallopian tube cancer, or advanced solid tumors, will be enrolled in the study in approximately 54 sites worldwide.
- In November 2024:- Merck Sharp & Dohme LLC- The purpose of this study is to determine the safety and efficacy of belzutifan in combination with pembrolizumab and lenvatinib in multiple solid tumors including hepatocellular carcinoma (HCC), colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer (BTC), endometrial cancer (EC),and esophageal squamous cell carcinoma (ESCC). There is no formal hypothesis testing in this study.
- In November 2024:- AstraZeneca- The objectives of this study are to assess safety and efficacy of Imfinzi (durvalumab) in a real world setting in patients treated with Imfinzi under the approved indication in Korea.
- In the 7MM, the United States accounted for the highest Biliary Tract Cancer market size, with nearly 48% of the market share of the Biliary Tract Cancer market as compared to EU4 and the UK and Japan in 2023.
- In 2023, among EU4 and the UK, Italy accounted for the largest Biliary Tract Cancer market size, while Spain accounted for the smallest share.
- Biliary tract cancers (Biliary Tract Cancer) constitute epithelial malignancies of the biliary tree and include the following: gallbladder cancer (GBC) and cholangiocarcinoma (CCA). CCA is further divided into intrahepatic CCA, perihilar CCA (Klatskin’s tumor), and distal CCA.
- The clinical features of Biliary Tract Cancer depend on the location of the tumor. Patients with extrahepatic tumors usually present with painless jaundice from biliary obstruction, and patients with intrahepatic tumors usually present with pain. Common complaints include pruritus, abdominal pain, malaise, fatigue, pruritus jaundice, and fever.
- Biliary tract cancer is usually diagnosed with the clinical examination of the abdomen, using imaging scans, ultrasound, magnetic resonance imaging (MRI) or computed tomography (CT), and biopsy.
- In 2023, Japan accounted for the highest number of total incident cases of Biliary Tract Cancer in the 7MM.
- In the United States, Biliary Tract Cancer occurs majorly in the age group of 70–79 years, constituting approximately ~30% of the total age-specific cases of Biliary Tract Cancer.
- Among the EU4 and the UK, the mutation-specific cases of Biliary Tract Cancer were highest in TP53 mutations, followed by KRAS mutations in 2023.
- The leading Biliary Tract Cancer Companies such as Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene and others.
- Promising Biliary Tract Cancer Therapies such as PEMAZYRE (pemigatinib), ROZLYTREK (entrectinib), VITRAKVI (larotrectinib), TIBSOVO (ivosidenib), LYTGOBI (futibatinib), KEYTRUDA (pembrolizumab), IMFINZI (durvalumab), TAFINLAR (dabrafenib) + MEKINIST (trametinib), and others.
Stay ahead in the Biliary Tract Cancer Therapeutics Market with DelveInsight’s Strategic Report @ Biliary Tract Cancer Market Outlook
Biliary Tract Cancer Epidemiology Segmentation in the 7MM
- Total Biliary Tract Cancer Incident Cases
- Biliary Tract Cancer Age-specific Cases
- Biliary Tract Cancer Stage-specific Cases
- Total Incident Cases of Biliary Tract Cancer by tumor location
- Biliary Tract Cancer Mutation-specific Cases
- Biliary Tract Cancer Treated Cases
Download the report to understand which factors are driving Biliary Tract Cancer epidemiology trends @ Biliary Tract Cancer Prevalence
Biliary Tract Cancer Marketed Therapies
- PEMAZYRE (pemigatinib): Incyte
PEMAZYRE is a kinase inhibitor indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. This indication is approved under accelerated approval based on the overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
- IMFINZI (durvalumab): AstraZeneca
IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated in combination with gemcitabine and cisplatin as treatment of adult patients with locally advanced or metastatic Biliary Tract Cancer.The approval for the treatment of adult patients with locally advanced or metastatic by the US FDA was based on the results from the TOPAZ-1 Phase III trial.
Emerging Biliary Tract Cancer Therapies
- CTX-009: Compass Therapeutics
CTX-009 is a bispecific antibody that simultaneously blocks Delta-like ligand 4/Notch (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization. Preclinical and early clinical data of CTX-009 suggest that blockade of both pathways provides robust antitumor activity across several solid tumors, including colorectal, gastric, cholangiocarcinoma, pancreatic, and non-small cell lung cancer. Partial responses to CTX-009 as monotherapy have been observed in heavily pre-treated patients with cancer who were resistant to currently approved anti-VEGF therapies.
- Zanidatamab: Jazz Pharmaceuticals/Zymeworks
Zanidatamab is a novel, late-stage oncology asset with the potential to transform the standard of care in multiple HER2-expressing cancers. It has demonstrated compelling data in biliary tract cancers and gastroesophageal adenocarcinoma with the potential to benefit patients across multiple tumor types.A pivotal Phase II clinical trial evaluating zanidatamab monotherapy in patients with previously treated advanced or metastatic HER2-amplified Biliary Tract Cancer.
Get In-Depth Knowledge on Biliary Tract Cancer Market Trends and Forecasts with DelveInsight @ Biliary Tract Cancer Treatment Market
Scope of the Biliary Tract Cancer Market Report
- Coverage- 7MM
- Biliary Tract Cancer Companies- Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, QED Therapeutics, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, BeiGene and others.
- Biliary Tract Cancer Therapies- PEMAZYRE (pemigatinib), ROZLYTREK (entrectinib), VITRAKVI (larotrectinib), TIBSOVO (ivosidenib), LYTGOBI (futibatinib), KEYTRUDA (pembrolizumab), IMFINZI (durvalumab), TAFINLAR (dabrafenib) + MEKINIST (trametinib), and others.
- Biliary Tract Cancer Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Biliary Tract Cancer Unmet Needs, KOL’s views, Analyst’s views, Biliary Tract Cancer Market Access and Reimbursement
Unlock Strategic Insights with DelveInsight’s Comprehensive Biliary Tract Cancer Market Report @ Biliary Tract Cancer Market Drivers and Barriers
Table of Content
1. Key Insights
2. Report Introduction
3. Executive Summary of Biliary Tract Cancer (BTC)
4. Key Events
5. Biliary Tract Cancer Market Overview at a Glance
6. Disease Background and Overview
7. Current Treatment Practices of Biliary Tract Cancer
8. Guidelines: Diagnosis and Treatment
9. Biliary Tract Cancer Epidemiology and Market Forecast Methodology
10. Biliary Tract Cancer Epidemiology and Patient Population
11. Biliary Tract Cancer Patient Journey
12. Marketed Biliary Tract Cancer Therapies
13. Emerging Biliary Tract Cancer Therapies
14. Biliary Tract Cancer (BTC) Market Analysis
15. Biliary Tract Cancer Unmet Needs
16. Biliary Tract Cancer SWOT Analysis
17. KOL Views
18. Biliary Tract Cancer Market Access and Reimbursement
19. Biliary Tract Cancer Market Access and Reimbursement
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/